Summary: Depletion of magnesium is observed in animal brain and in human blood after brain injury. Treatment with magnesium attenuates the pathological and behavioral changes in rats with brain injury; however, the therapeutic effect of magnesium has not been consistently observed in humans with traumatic brain injury (TBI). Secondary brain insults are observed in patients with brain injury, which adversely affect clinical outcome. Systemic administration studies in rats have shown that magnesium enters the brain; however, inducing hypermagnesemia in humans did not concomitantly increase magnesium levels in the CSF. We hypothesize that the neuroprotective effects of magnesium in TBI patients could be observed by increasing its brain bioavailability with mannitol. Here, we review the role of magnesium in brain injury, preclinical studies in brain injury, clinical safety and efficacy studies in TBI patients, brain bioavailability studies in rat, and pharmacokinetic studies in humans with brain injury. Neurodegeneration after brain injury involves multiple biochemical pathways. Treatment with a single agent has often resulted in poor efficacy at a safe dose or toxicity at a therapeutic dose. A successful neuroprotective therapy needs to be aimed at homeostatic control of these pathways with multiple agents. Other pharmacological agents, such as dexanabinol and progesterone, and physiological interventions, with hypothermia and hyperoxia, have been studied for the treatment of brain injury. Treatment with magnesium and hypothermia has shown favorable outcome in rats with cerebral ischemia. We conclude that coadministration of magnesium and mannitol with pharmacological and physiological agents could be an effective neuroprotective regimen for the treatment of TBI.
INTRODUCTION
Traumatic brain injury (TBI) occurs when a sudden trauma causes damage to the brain. TBI affects people of all ages and manifests itself with high morbidity and mortality. The events following TBI in morbid patients result in permanent disability with lifelong financial, medical, emotional, family, and social consequences.
A depletion of magnesium has been observed in brain of animals and in blood of humans after brain injury. Administration of magnesium attenuated the neurobehavioral and pathological changes in animal models of brain injury. In TBI patients, however, two prospective clinical studies with magnesium as a neuroprotective agent showed conflicting results.
1,2 Secondary brain insults and other parameters have been observed to adversely affect the clinical outcome in patients with brain injuries, and these could have unfavorably affected the results of the clinical studies on therapeutic efficacy of magnesium in TBI patients. Pharmacokinetic and pharmacodynamic studies in normal rats have shown that after systemic administration magnesium was able to enter the brain, 3, 4 but pharmacokinetic studies in humans with brain insults have shown that parenteral administration of magnesium did not cause a concomitant rise of magnesium in the CSF. [5] [6] [7] Regulation of brain and CSF by the central nervous system may limit the blood-brain barrier (BBB) permeability for peripherally administered magnesium, which could be a limiting factor in its efficacy in TBI patients.
Multiple biochemical pathways are involved in the brain degeneration process that follows TBI. Treatment with a single agent may result in lack of efficacy at a safe dose or adverse effects at a therapeutic dose or upon repeated administration. A clinically successful neuroprotective therapy must be aimed at controlling these pathways with multiple agents, for a synergetic affect. Besides magnesium, several pharmacological agents 8, 9 and physiological interventions, such as hyperoxia and hypothermia (reviewed elsewhere in this issue), are being studied for the treatment of TBI. Among the phar-macological agents, dexanabinol and progesterone have been studied in clinical trials. Dexanabinol was safe but not efficacious in a phase III study. 10 Progesterone is currently in a phase III clinical study (http://www.Clinicaltrials.gov Identifier: NCT00822900). We hypothesize that increasing brain bioavailability of magnesium with mannitol, along with cotherapy with pharmacological agents and physiological interventions at their safe and lowest-effective doses could lead to a clinically effective neuroprotective regimen for the treatment of TBI.
PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY
The pathophysiology of TBI occurs in two phases, a primary phase and a secondary phase. During the primary phase, there is localized neuronal death at the site of impact as a direct consequence of the biomechanical injury. During this phase, there is a decrease in cerebral blood flow, resulting in hypoxia and ischemia with an increase of brain oxidative metabolism. 11, 12 A shortage of glucose and an acute increase in energy demand results in anaerobic metabolism of glucose (hyperglycolysis) and release of lactate. These exacerbate the effects of the primary physical insult. An accumulation of lactate and decrease in glucose concentration have been observed in TBI patients. 13, 14 An increase in lactate to pyruvate (L/P) ratio is a sensitive indicator of brain ischemia, and increases in L/P ratio have been observed after subarachnoid hemorrhage. 15, 16 Brain edema of cellular nature is frequently observed, which results in an increase of intracranial pressure (ICP) for more than 5 days. 17 Increased ICP causes structural damage and herniation and reduces cerebral perfusion pressure and cerebral blood flow, leading to further exacerbation of ischemia. In TBI patients, ICP Ͼ 20 mmHg has been shown to contribute to neurological deterioration and mortality. 18 The primary phase activates the subsequent and irreversible secondary phase, with long-term effects. During this secondary phase, several imbalances in the biochemical homeostatic pathways and factors contribute to the cascade of events resulting in irreversible neuronal degeneration and death, distal to the injured site. Excitotoxicity with excessive release of glutamate 19 occurs and causes an overstimulation of the postsynaptic NMDA receptors that control the ionic channels. (Some glutamate is also released as a result of hypoxia, in the primary phase.) There is a failure of calcium homeostasis and a massive influx of sodium, calcium, and water, with delayed calcium deregulation. Ischemia due to increased ICP in the primary phase also adversely affects the secondary phase. Generation of oxygen free radicals and mitochondrial dysfunctions lead to calcium accumulation, depletion of ATP, generation of reactive oxygen species, and apoptosis. 20, 21 Together, these events result in neurodegeneration.
MECHANISMS OF NEUROPROTECTIVE ACTION OF MAGNESIUM
Magnesium has an important role in homeostatic regulation of the pathways involved in the delayed secondary phase of brain injury. 22 During normal physiological processes, magnesium is a noncompetitive inhibitor of the NMDA receptors 23 and it thereby regulates calcium influx. 24 In the cascade of events following TBI, there is a depletion of magnesium and its homeostatic control of the NMDA receptors is lost. This leads to a massive influx of calcium, resulting in neuronal degeneration and cell death. 22 Magnesium deficiency was associated with increased oxidative stress in rats through a reduction in plasma antioxidants and increased lipid peroxidation, possibly due to increased susceptibility of body organs to free radical injury. 25 Administration of magnesium to dogs during coronary occlusion attenuated the increase of free radicals during reperfusion. 26 These findings were confirmed in TBI patients: administration of magnesium sulfate reduced oxidative stress after TBI in humans. 27 In patients with subarachnoid hemorrhage undergoing temporary cerebral artery occlusion for clipping of cerebral aneurysm, treatment with magnesium sulfate dilated the leptomeningeal arteries and enhanced collateral blood flow and tissue oxygenation. 28 Molecular mechanisms have been studied on the efficacy of magnesium in attenuating the neurological damage in TBI. The tumor-suppressor gene TP53 (alias p53) encodes the cellular tumor antigen p53 and is a regulator of neuronal apoptosis. Upregulation of TP53 mRNA was observed in the cortex, thalamus, and hippocampus after brain injury in rats. 29 Treatment with magnesium reduced the upregulation of the TP53 gene and apoptosis in rats with brain injury. 30 Water homeostasis is critical for optimal neuronal function, and any alteration of intracellular and extracellular water content will disrupt ionic homeostasis and electrical conduction. 31 Aquaporin-4, a membrane protein found in brain astrocytes of mammals, has an important role in the homeostasis of water. It is upregulated in brain injury, and thus leads to an increase in brain water content resulting in brain edema. In rats with brain injury, magnesium downregulated aquaporin-4 channels 32 and thereby attenuated brain edema.
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PRECLINICAL STUDIES WITH MAGNESIUM IN BRAIN INJURY
A disruption of magnesium homeostasis has been observed after brain injury, and normalizing magnesium levels has resulted in improved neurological recoveries. A decline in ionized magnesium concentrations in rat brain was observed after brain injury that correlated with neurological outcome and behavioral deficits in rats. 34 A significant positive and linear correlation was established between ionized magnesium levels measured at 24 h after injury and motor outcome at 1 and 2 weeks. 35 Several studies in rats have shown that treatment with magnesium after brain injury had neuroprotective effects on motor and behavioral outcome 22,36 -38 in a dose-dependent manner. 39, 40 Cortical damage was attenuated after treatment with magnesium in rats. 41 Magnesium administered at 24 h improved motor outcome and behavioral parameters in rats with brain injury. 42, 43 Magnesium reversed persistent motor and cognitive deficits with reduction of post-traumatic stress and anxiety after brain injury in rats. 44 Magnesium therapy after TBI may not always improve the mortality and morbidity of the subjects. In patients with severe TBI, a subdural hematoma is often present, which has developed subsequent to the primary injury. In a rat model of impact acceleration, diffuse brain trauma frequently caused extensive subdural hematoma. 45 In rats diagnosed with subdural hematoma from postmortem examination, previous postinjury administration of magnesium did not show improvement in motor activity. In rats with no subdural hematoma, administration of magnesium did show significant improvement in motor activity. The free magnesium concentration in brains of the magnesium-treated, hematoma group demonstrated a biphasic decline. There was an initial and immediate decline, recovery of brain magnesium levels subsequent to magnesium treatment, and then a subsequent decline again. The subsequent decline in brain magnesium concentration was not observed in the magnesium-treated, no hematoma group of rats. Development of subdural hematoma after brain injury resulted in a decline of brain magnesium concentration, even after magnesium treatment. 45 
MAGNESIUM IN HUMANS WITH TRAUMATIC BRAIN INJURY
Disruption of magnesium homeostasis has been observed in the pathophysiological events after TBI in humans. In TBI patients, a graded deficit of serum ionized magnesium concentration has been observed 46 that represents an early indicator of ultimate, irreversible brain damage. An early measurement of ionized magnesium could be a clinically useful predictor of the late outcome after head injury. 47 Increased urinary loss of magnesium after TBI in humans appears to be one of the factors contributing to its depletion. 48 Ionized magnesium is the physiologically active form that can enter the brain. Its levels are affected by the total magnesium concentration in the CSF, and CSF magnesium concentration is used as a surrogate marker of brain magnesium concentration. 6 In a comparative analysis of serum and CSF magnesium concentrations in TBI patients with a mean Glasgow Coma Scale (GCS) score of 8.7, serum ionized magnesium concentration correlated with the GCS scores. 49 In another study, elevated magnesium levels were observed in the ventricular CSF of TBI patients with a mean GCS score of 5.6. 50 In humans with graded TBI with GCS scores of 4 -6 (extensive, penetrating injury) and 13-15 (mild, closed injury), a time-dependent increase of plasma ionized magnesium was observed for 7 days. 27 There was a persistent production of reactive oxygen species malondialdehyde and a delayed decrease of the antioxidant superoxide dismutase, suggesting increased antioxidant utilization. The study showed a correlation between the decline in plasma ionized magnesium concentration and the development of oxidative stress in TBI. 27 
CLINICAL STUDIES WITH MAGNESIUM IN TRAUMATIC BRAIN INJURY Safety and tolerability studies with magnesium
In the Turin Lidomag Pilot Study, a high dose of magnesium with a low dose of lidocaine was administered for 3 days to 32 patients with severe TBI and a GCS score of 3-8. 51 Magnesium was administered intravenously at an initiation dose of 70 mg/kg, followed by a maintenance dose of 15 mg/kg per hour. Lidocaine was administered intravenously at an initiation dose of 1.5 mg/kg, followed by a maintenance dose of 1 mg/kg per hour. The patients were monitored for 6 months. The study showed that a combination of magnesium and lidocaine was safe and well tolerated, with lesser mortality.
The safety of magnesium was studied in pediatric patients suffering from TBI. 52 Six patients with ages ranging from 3.4 to 15.4 years and GCS scores of 3-11 were recruited, four of whom were placed on magnesium dosing within 17-56 h of injury; the other two patients served as controls and were administered normal saline. Magnesium was administered intravenously at an initiation dose of 50 mg/kg and a maximal dose of 4 g, administered over 30 min; this was followed by a maintenance dose of 8.3 mg/kg per hour, administered intravenously, for 24 h. A follow-up examination with neuropsychological testing and cranial MRI at 3 months after the injury showed no adverse hemodynamic effects.
Efficacy studies with magnesium
In contrast to the preclinical studies, clinical studies with magnesium treatment after TBI have failed to show consistent beneficial effects. In particular, two prospective clinical studies have reported differing effects of magnesium in TBI patients.
1,2
In a double-blind clinical trial reported by Temkin et al., 1 the effects of two doses of magnesium sulfate were studied in 499 patients with moderate to severe TBI. Magnesium was administered intravenously within 8 h of injury at a loading dose, followed by a continuous infusion for 5 days. The higher dose was targeted to achieve serum levels of 1.25-2.5 mmol/L. A high mortality was observed at 6 months, and the magnesium dose was lowered to achieve serum levels of 1.0 -1.85 mmol/L. No beneficial effects were observed with a composite primary outcome measure based on mortality, seizures, measures of functional status, and neuropsychological tests conducted at 6 months.
In this clinical trial, the patients upon admission had a 1) GCS score of 3-12, or 2) needed intracranial surgery within 8 h of injury, or 3) if intubated, had a GCS motor score of 1-5 without pharmacological paralysis.
1 A better composite outcome was observed at 6 months with both the low and high doses of magnesium in patients with moderate severity of injury. No data were reported to correlate the severity of injury with the dose of magnesium or placebo and mortality. Had this been done, the results might have been interpreted differently.
A correlation between age and morbidity has been observed in TBI patients. In a study on the effects of age on outcome in 235 TBI patients, lower Functional Independence Measure (FIM) scores were observed at 6 months in patients above 65 years of age, compared with younger patients. 53 In the clinical trial reported by Temkin et al. 1 on magnesium in TBI, the exclusion criteria excluded patients less than 14 years of age; no upper limit of age was reported, and the mean age for all the patients was 34.3 years (SD, 16.6) for both the high-dose and low-dose magnesium groups and 34.4 years (SD, 17.8) for the placebo group. The patients were stratified into two groups, with ages below and above 40 years. In the placebo groups, better composite outcome was observed in patients below 40 years than the patients above 40 years. In the patients below 40 years, however, no difference on composite outcome was observed between either the low or high doses of magnesium and placebo treatments. In patients above 40 years, the group with a high dose of magnesium showed better outcome than the placebo group, but the low-dose group did not show any difference from the placebo group. Any correlations among severity of injury, age, treatment, and outcome were not reported.
A correlation between age, morbidity at discharge, and outcome was reported in yet another prospective multicenter trial. 54 In that study of 236 patients, the TBI patients above 60 years who were discharged with a Glasgow Outcome Score (GOS) of less than 4 showed lower FIM Scores at 1 year, compared with younger patients. In the clinical trial reported by Temkin et al., 1 no data on GOS (or any other scoring system) upon discharge were reported. Inclusion of data on severity of injury, age, and outcomes at discharge and at 6 months might have allowed different interpretation of the results.
Hypotension and hypoxia, frequently observed after TBI, contribute to increased morbidity and mortality. A prospective study of 717 TBI patients has shown 50% mortality in those with systolic blood pressure (SBP) less than 90 mmHg and 57% mortality in patients with both hypotension and hypoxia with a PaO 2 less than 60 mmHg, compared with 27% mortality in patients without any hypotension and hypoxia. 55 A mortality of 83% was observed in TBI patients with a SBP below 90 mmHg within 24 h of admission, compared with 45% in patients with SBP above 90 mmHg. 56 In a study of 107 patients, a linear correlation was observed between the number of hypotensive episodes with SBP below 90 mmHg and mortality during initial resuscitation. 57 Patients with one hypotensive episode had a 53% mortality rate, whereas 100% mortality was observed in patients with three or more hypotensive episodes. No effect of hypoxia on mortality was observed.
In the clinical trial reported by Temkin et al. 1 on magnesium in TBI patients, the predosing mean SBP for the combined group patients treated with low or high doses of magnesium was 128 mmHg (SD, 23) and 129 mmHg (SD, 20) for the placebo group. The diastolic blood pressure for the combined patients was 77 mmHg (SD, 17) for the magnesium group and 77 mmHg (SD, 15) for the placebo group. The blood pressure at admission was not reported. During treatment with both low and high doses of magnesium and placebo, hypotensive episodes with SBP below 90 mmHg was reported in 26 -36% of the patients. Correlation of hypotensive episodes with mortality or composite outcome was not reported. 1 Physiological response to head injury leads to increased release of cortisol, glucagon, and epinephrine, resulting in gluconeogenesis and stress hyperglycemia. In a prospective study of 267 patients with differing severity of head injuries, patients with severe head injury had more hyperglycemia, with glucose levels above 200 mg/dL, than patients with moderate injury. 58 The patients with glucose levels above 200 mg/dL also showed increased ICP and unfavorable outcome. In a retrospective review of 516 patients, hyperglycemia with glucose levels above 200 mg/dL in the first 24 h after brain injury and on days 1-2 after admission was associated with significantly greater infection and mortality. 59 In 338 patients with severe TBI, the mean arterial pressure and blood glucose levels linearly correlated with mortality, with a stronger relationship between hyperglycemia and increased mortality. 60 In a prospective study of 896 critically ill trauma patients, early glycemic control resulted in reduced infection and mortality. 61 In the clinical trial reported by Temkin et al. 1 on magnesium in TBI pa-tients, blood glucose levels were not reported, and it remains unknown whether blood glucose levels adversely affected morbidity and mortality in these patients. Excessive magnesium is known to cause or exacerbate renal failure. The patients in the clinical trial reported by Temkin et al. 1 were not screened for renal function, and their urine output was not reported. The time from treatment to death was not reported. Non-neurological organ dysfunction is commonly observed in TBI patients and contributes independently to a worse clinical outcome. 62 It is not clear whether patients in the Temkin et al. 1 trial died from the effects of magnesium or from natural progress of brain injury. It was also not reported whether the patients had any preexisting health conditions, and whether they were on other medications or whether the consumed alcohol, tobacco, or had a history of substance abuse.
In another prospective clinical study, reported by Dhandapani et al., 2 magnesium sulfate was administered within 12 h of injury to 30 patients with severe closed TBI at initiation doses of 4 g, administered intravenously, over 5-10 minutes and 10 g, administered intramuscularly, followed by a maintenance dose of 5 g administered intramuscularly every 4 h for 24 h. The inclusion criteria included patients with closed-head TBI, admission GCS score of 5-8, and age 18 -60 years. The exclusion criteria included patients with hypotension with a SBP below 90 mmHg for more than 10 minutes, renal failure, and significant multisystem injury. At the end of 3 months, mortality was 13% for the patients treated with magnesium and 47% for the patients treated with placebo. Among the surviving patients, good recovery at 3 months was observed in 54% of the patients treated with magnesium and in 38% of the patients on placebo. The patient outcome was evaluated using the 5-point GOS, which may produce false positives. The 8-point GOS-Extended (GOS-E) has been developed to improve on the 5-point GOS. It was not reported whether the study was blinded. The patients were evaluated for only 3 months, whereas the standard evaluation period in most brain injury studies is at least 6 months. The admission blood pressure and blood glucose levels were not reported.
Secondary insults in traumatic brain injury
Secondary insults have been observed after TBI that adversely affect the clinical outcome and mortality. Hypotension has been related with increased mortality, and hypoxia, hypocapnia, increased ICP, and acidosis were associated with poor outcome. 63 From the two prospective clinical trials of magnesium in TBI reported by Temkin et al. 1 and Dhandapani et al., 2 it is evident that in clinical trials on brain injuries a study design with more stringent inclusion-exclusion criteria need to be considered, to account for secondary brain insults and parameters likely to adversely affect outcome, such as severity of head injury, multiorgan injury, age limits, renal function, pre-existing health conditions, concomitant medication, use of tobacco and alcohol, and history of substance abuse.
BRAIN BIOAVAILABILITY OF SYSTEMICALLY ADMINISTERED MAGNESIUM
Preclinical studies Pharmacokinetic studies in rats have shown that after intraperitoneal administration of magnesium sulfate, increased levels of magnesium were observed in the cortex and hippocampus. 3 In a recent pharmacodynamic study, daily intraperitoneal administration of magnesium chloride in rats prior to the acquisition of learning a reference memory task in the Morris water maze produced significant amnesia after 3 days. 4 Both of these studies proved that after systemic administration, magnesium was able to enter the brain in rats with intact BBB.
Clinical studies
A marginal increase of magnesium in the CSF was observed after administration of magnesium sulfate intravenously in women with preeclampsia (n ϭ 10). 7 In another study of 20 patients undergoing craniotomy, magnesium sulfate administered intravenously at 60 mg/kg over 15 minutes produced a maximal plasma magnesium concentration at 30 minutes, with subsequent decreases. However, a significant increase of magnesium in the CSF after 90 minutes, which persisted for more than 4 hours, was observed. A correlation between plasma and CSF magnesium concentrations was not observed. Of the 20 patients, 15 were also administered 0.5 mL/kg of mannitol intravenously for better operating conditions. 5 This dose and route of mannitol should not cause BBB disruption.
In another clinical study, 30 patients with acute brain injury secondary to subarachnoid hemorrhage, TBI, primary intracerebral hemorrhage, subdural hematoma, brain tumor, brain infection, or ischemic stroke were administered an intravenous bolus dose of magnesium sulfate at 20 mmol (5 g) over 30 minutes. The treatment was given on an average of 5 days after the injury (range, 1-16 days) and was followed by an infusion of magnesium sulfate at 8 mmol/h (2 g/h), which was adjusted to achieve a serum total magnesium range of 2.1-2.5 mmol/L. The magnesium infusion was terminated at 24 h from the beginning of bolus dose. Although the serum total magnesium increased by 169% and the ionized magnesium increased by 132% from baseline at 12 h, the CSF total magnesium increased by 15% and the CSF ionized magnesium increased by 11%. 6 Key tenets for a neuroprotective agent include 1) entry into the brain, 2) presence in the brain at a concentration known to be neuroprotective, and 3) presence of an adequate concentration in the brain for a period of time that will improve neuronal survival. 6 It is evident that after systemic administration in rats with intact BBB, magnesium entered the brain and induced behavioral changes. In humans, however, inducing hypermagnesemia resulted in marginal increase of CSF total and ionized magnesium concentration. Also, the relationship between blood and CSF magnesium concentrations changed with time. From pharmacokinetic studies in humans, it can be concluded that blood magnesium concentration cannot be used to predict the CSF magnesium concentration.
COMBINATION OF MAGNESIUM WITH PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY
Neuronal degeneration during the secondary phase of brain injury after TBI is mediated through multiple biochemical pathways. For clinical success, a neuroprotective therapy must address the homeostatic control of these pathways with a combination of pharmacological agents.
Preclinical studies
Coadministration of magnesium with pharmacological and nutritional agents has been studied successfully in preclinical models of brain insult. A combination therapy with magnesium and the antioxidant tirilazad significantly improved neurological function and reduced infarct volume in rats with cerebral ischemia. 64 A combination of magnesium with vitamin B 2 (riboflavin) significantly improved functional recovery in rats subjected to cortical contusion injury.
65
Clinical studies
Pharmacological agents evaluated preclinically for the treatment of brain injury include statins, progesterone, erythropoietin, minocycline, Toll-like receptor agonists, dexanabinol, thyrotropin releasing hormone analogs, and cyclosporin A. 8, 9 Of these, dexanabinol and progesterone have been studied clinically for the treatment of TBI.
A synthetic analog of tetrahydrocannabinol, dexanabinol, has neuroprotectant properties as an NMDA receptor antagonist, free radical scavenger, antioxidant, and inhibitor of tumor necrosis factor-␣. 66 -68 A phase II clinical study of 67 patients, 6-month post-injury follow-up, concluded that dexanabinol was safe and well tolerated in patients with severe TBI with significant control of ICP and cerebral perfusion pressure, and without lowering of SBP to less than 90 mmHg. 69 However, a phase III randomized placebo-controlled clinical study of dexanabinol in 861 TBI patients reported it to be safe but not efficacious.
Sex alters the incidence and recovery from TBI, with men experiencing more injury than women. The female steroidal hormone progesterone has been studied as a neuroprotectant in animal models of brain injury. In an in vitro model of spinal cord injury, progesterone protected against glutamate-mediated toxicity. 70 Progesterone was effective against oxidative stress in in vitro studies. 71 Progesterone attenuated brain edema 72 and reduced inflammation 73 in rats with brain injury. In male and ovariectomized female rats with brain injury, treatment with progesterone improved their motor and cognitive performance with attenuation of caspase-3 immunoreactivity and reduction of axonal injury. 74 In the phase II ProTECT clinical study in 100 patients with acute TBI, treatment with progesterone was safe and a 30-day post-injury follow-up showed lower mortality. Also, moderate to good clinical outcome with improved GOS-E scores were observed in patients with moderate TBI (initial GCS 9 -12), but no differences were observed between progesterone treatment and placebo groups for patients with severe TBI. 75 In another clinical study in 159 patients with acute severe TBI (initial GCS Ͻ 8), treatment with progesterone significantly improved neurological outcome at 6 months. 76 A phase III clinical study with progesterone in TBI patients is under way (http://www.Clinicaltrials.gov Identifier: NCT00822900).
COMBINATION OF MAGNESIUM WITH PHYSIOLOGICAL INTERVENTIONS FOR THE TREATMENT FOR TRAUMATIC BRAIN INJURY
Preclinical studies with magnesium and hypothermia A combination therapy with magnesium and hypothermia reduced neuronal death 77 and infarct volume 78 in rats with cerebral ischemia. A synergistic reduction in infarct volume was observed with the combination of magnesium, tirilazad, and hypothermia in rats with cerebral ischemia 79 in a post-injury time-dependant manner. 80 
Clinical studies with hypothermia
Clinical studies with moderate hypothermia of 32°C to 35°C for 1-14 days have shown a beneficial effect on outcome in TBI patients with lowering of ICP [81] [82] [83] [84] and increase of cerebral perfusion pressure. 83 However, two multicenter studies have failed to show beneficial effects of hypothermia. 85, 86 In infants and children, hypothermia treatment has shown preservation of oxidative defenses in the CSF after TBI. 87 A meta-analysis of the clinical trials has shown that hypothermia reduced mortality and improved neurological outcome, although this was offset with an increased risk of pneumonia. 88 No combination effects of magnesium and hypothermia have been reported in humans with TBI.
Clinical studies with hyperoxia
Management of hospitalized TBI patients should include adequate oxygen delivery to the brain with a decrease of lactate levels and L/P ratio, representing a reversal of tissue hypoxia and an increase in cerebral metabolism. It is hypothesized that hyperoxia increases plasma oxygen content and thereby enhances tissue oxygen tension and mitochondrial function. 89 A recent study in TBI patients has shown that hyperoxia restores mitochondrial function. 90 Treatment of TBI patients with normobaric hyperoxia has shown variable results. Significant improvement 91, 92 or no improvement 93 in cerebral metabolism, a decrease of lactate levels, 91,94 -96 a reduction of ischemic brain volume 92 and ICP 96 were observed. Hyperoxia treatment has also resulted in either no change 92 and in only some studies a decrease 90, 96 of L/P ratio. No combination effects of magnesium and hyperoxia have been reported in humans with TBI.
CONCLUSION
The success of magnesium in attenuating the process of neurodegeneration in animal models of brain injury has been widely studied; however, preclinical studies have not yet been translated into successful clinical outcome. In TBI patients, administration of magnesium has shown varied results. Secondary brain insults and other parameters adversely affect the clinical outcome, and these could have unfavorably influenced the result of the efficacy studies with magnesium in TBI patients. In the design of clinical studies on brain injuries, secondary brain insults and parameters adversely affecting outcome need to be considered.
Pharmacokinetic and pharmacodynamic studies in normal rats have shown that after intraperitoneal administration magnesium can cross the BBB and enter the brain. In humans with brain insults, however, parenteral administration of magnesium resulted in low bioavailability in the CSF. This could have been a factor in the failure of magnesium to show consistent efficacy in clinical treatment of TBI. Increasing brain bioavailability of parenterally administered magnesium by disruption of the BBB is a necessary step in assessing the therapeutic benefits of magnesium after TBI.
In TBI patients, a serum concentration of magnesium at 1.25-2.5 mmol/L increased mortality. 1 Dexanabinol was safe and efficacious in a Phase II clinical study; in a Phase III study, it was safe but not efficacious. A phase II study with progesterone reported no discernible harm with signs of benefit, and a phase III study is underway. Hyperoxia caused injury to the eye, lungs, heart, brain, and gastrointestinal tract and induced seizures 97 and cerebral vasoconstriction. 98 It is apparent that use of a single agent at a safe dose lacks efficacy and that adverse effects are observed at therapeutic doses or upon repeated administration. Multiple pathways are involved during the secondary phase of brain injury. Judicious combination of pharmacological agents and physiological interventions at safe and lowest effective doses are necessary for synergistic control of the pathways involved in the secondary phase of injury. Increasing brain bioavailability of magnesium using mannitol can allow for a low and safe dose of magnesium to be administered and promises to improve clinical outcome in TBI patients. Combination of magnesium and mannitol with pharmacological agents such as dexanabinol and progesterone and interventions with hyperoxia or hypothermia could be a safe and clinically successful neuroprotective regimen for the treatment of TBI.
